EBITDA Margin: Earnings before interest, taxes, depreciation and amortization as a portion of total revenue. Calculated as: EBITDA / Total Revenues
CytoMed Therapeutics Limited (GDTC) had EBITDA Margin of -584.75% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$0.25M |
|
$-3.10M |
|
-- |
|
$0.25M |
|
$2.04M |
|
$-1.79M |
|
$-1.32M |
|
$-3.11M |
|
$-3.11M |
|
$-3.11M |
|
$-3.11M |
|
$-3.11M |
|
$-3.11M |
|
$-1.79M |
|
$-1.48M |
|
11.65M |
|
11.65M |
|
$-0.27 |
|
$-0.27 |
|
| Balance Sheet Financials | |
$2.85M |
|
$2.87M |
|
$3.36M |
|
$6.21M |
|
$0.55M |
|
$0.33M |
|
$0.33M |
|
$0.88M |
|
$5.33M |
|
$5.23M |
|
$5.33M |
|
11.83M |
|
| Cash Flow Statement Financials | |
$-2.88M |
|
$0.72M |
|
$0.16M |
|
$3.65M |
|
$1.63M |
|
$-2.02M |
|
$0.54M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.17 |
|
-- |
|
-- |
|
0.06 |
|
0.07 |
|
100.00% |
|
-708.54% |
|
-708.54% |
|
|
EBITDA Margin |
-584.75% |
-1231.96% |
|
-1227.07% |
|
$-3.37M |
|
-- |
|
-- |
|
-- |
|
0.04 |
|
-- |
|
0.21 |
|
1763.73 |
|
-58.31% |
|
-59.39% |
|
-50.05% |
|
-54.93% |
|
$0.45 |
|
$-0.29 |
|
$-0.25 |
|